| Barriers and facilitators for cascade testing in genetic conditions: a systematic review S Srinivasan, NY Won, WD Dotson, ST Wright, MC Roberts European Journal of Human Genetics 28 (12), 1631-1644, 2020 | 82 | 2020 |
| miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis N Benderska, AL Dittrich, S Knaup, TT Rau, C Neufert, S Wach, ... Inflammatory bowel diseases 21 (9), 2039-2051, 2015 | 75 | 2015 |
| Barriers and facilitators for population genetic screening in healthy populations: a systematic review EC Shen, S Srinivasan, LE Passero, CG Allen, M Dixon, K Foss, ... Frontiers in Genetics 13, 865384, 2022 | 21 | 2022 |
| Stakeholder perspectives on overcoming barriers to cascade testing in Lynch syndrome: a qualitative study S Srinivasan, H Hampel, J Leeman, A Patel, A Kulchak Rahm, ... Cancer Prevention Research 13 (12), 1037-1046, 2020 | 14 | 2020 |
| Uptake of genetic testing among patients with cancer at risk for Lynch syndrome in the national health interview survey KEV Actkins, S Srinivasan, LP Spees, E Turbitt, CG Allen, MC Roberts Cancer Prevention Research 14 (10), 927-932, 2021 | 7 | 2021 |
| Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer OL Osazuwa-Peters, LE Wilson, DK Check, MC Roberts, S Srinivasan, ... Clinical lung cancer 24 (4), 305-312, 2023 | 2 | 2023 |
| Development and initial testing of a multi-stakeholder intervention for Lynch syndrome cascade screening: an intervention mapping approach L Passero, S Srinivasan, ME Grewe, J Leeman, J Berg, D Reuland, ... BMC Health Services Research 22 (1), 1411, 2022 | 2 | 2022 |
| MSR38 Can Logistic Regression (LOR) Better Predict the Significance of the Overall Survival (OS) from Surrogate Endpoints (SES) for Randomized Controlled Trials (RCTS) in … O Alagoz, S Srinivasan, I Kim, M Kurt Value in Health 25 (12), S357, 2022 | 1 | 2022 |
| Examining the role of language competency in genetic testing awareness among adults in the United States L Passero, S Srinivasan, MC Roberts Journal of Genetic Counseling 31 (5), 1054-1061, 2022 | 1 | 2022 |
| MSR97 Indirect Estimation of Post-Distant Recurrence Survival (PDRS) for Resected Stage II/III Melanoma: A Network-Meta Analysis (NMA) Approach M Kurt, K Toor, Y Zhang, C Smare, C Theriou, K Chan, S Srinivasan, ... Value in Health 27 (6), S278, 2024 | | 2024 |
| CO153 Predicting Overall Survival (OS) Benefit in Previously Untreated Metastatic Melanoma From Improvements in Response Outcomes: A Correlation Meta-Analysis of Randomized … L Leung, P Serafini, S Srinivasan, F Ejzykowicz, MM Pourrahmat, ... Value in Health 27 (6), S46, 2024 | | 2024 |
| CO115 Long-Term Post-Recurrence Survival (PRS) Outcomes for Stage IIB/C Melanoma Patients in Real-World (RW) Settings: Analyses from a Longitudinal Electronic Health Record … M Kurt, Y Zhang, S Srinivasan, M Dyer, A Moshyk, K Shelley Value in Health 27 (6), S38, 2024 | | 2024 |
| EE47 Cost Per Recurrence-Free Survivor (CPRS) and Cost Per Recurrence-Free Life Month (CPRLM) of Adjuvant Nivolumab (NIVO) Versus Pembrolizumab (PEMBRO) Among Patients With … JM Davis, S Srinivasan, EX Du, C Xu, J Linton, K Betts, K Shelley Value in Health 27 (6), S65, 2024 | | 2024 |
| Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data JC Moser, S Bhatia, A Amin, AC Pavlick, KA Betts, EX Du, T Poretta, ... Cancer Immunology, Immunotherapy 73 (7), 116, 2024 | | 2024 |
| MSR12 Analysis of Long-Term Survivorship (LTS) Rates for Stage 2B/2C Melanoma Using Published Real-World Data (RWD) and Data From Randomized Controlled Trials (RCTS) O Alagoz, A Winge-Main, S Srinivasan, M Dyer, R Wolf, SH Thybo, ... Value in Health 26 (12), S395, 2023 | | 2023 |
| CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized … L Leung, J Kirkwood, S Srinivasan, M Dyer, A Qian, MM Pourrahmat, ... Value in Health 26 (12), S24, 2023 | | 2023 |
| P49 Evaluation of Surrogate Endpoints (SES) for Previously Untreated Unresectable or Metastatic Melanoma (MMEL): Analyses from a Longitudinal Electronic Health Record Database … L Leung, P Mohr, P Serafini, S Kanters, MM Pourrahmat, A Moshyk, ... Value in Health 26 (6), S11, 2023 | | 2023 |
| An indirect assessment of individual-level association between disease-free survival (DFS) and overall survival (OS) for resectable esophageal or gastroesophageal junction … O Alagoz, JA Ajani, S Srinivasan, I Kim, P Singh, M Kurt Journal of Clinical Oncology 41 (4_suppl), 369-369, 2023 | | 2023 |
| MSR104 Assessing the Impact of Integrating Extrapolated Long-Term Outcomes Into Elicitation of Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS … O Alagoz, S Srinivasan, H Xiao, P Singh, J Gricar, M Dixon, I Kim, M Kurt Value in Health 25 (12), S370, 2022 | | 2022 |
| MSR12 Eliciting Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): A Non-Parametric Linear Optimization Approach O Alagoz, S Srinivasan, H Xiao, P Singh, J Gricar, M Dixon, I Kim, M Kurt Value in Health 25 (7), S519-S520, 2022 | | 2022 |
Megan RobertsUNC Eshelman School of PharmacyVerified email at unc.edu
